News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Celgene Revlimid Drug Trial Temporarily Suspended
April 11, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON, April 11 (Reuters) - A trial of Celgene Inc.'s (CELG.O: Quote, Profile , Research) cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, or SWOG, which was running the late-stage trial.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
MORE ON THIS TOPIC
Insights
Multispecifics are transforming the CDMO development architecture
August 28, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Drug Development
Generate Bio drops as data accidentally leaked ahead of European conference
August 27, 2026
·
2 min read
·
Gabrielle Masson
Immunology and inflammation
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
August 27, 2026
·
2 min read
·
Tristan Manalac
Insights
Fragile X at a turning point: Breaking through the clinical bottleneck
August 27, 2026
·
1 min read
·
Jennifer C. Smith-Parker